Radiopharm Theranostics Ltd (RADX)
Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers). Other significant developments include RAD 101 and RAD 102 for brain metastases, RAD 402 for advanced prostate cancer, and RV01 for multiple solid tumors. To accelerate the clinical progression of its radiopharmaceutical assets, Radiopharm Theranostics maintains a strategic partnership with Lantheus Holdings, Inc.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Radiopharm Theranostics Limited
NASDAQ:RADXHealthcare · Biotechnology
-3.26%$1.08
AH$1.08+0.00%vs close
Mkt Cap$16.96M
Float9.34M
O/S15.7M
Vol
$ Vol
RVOL
Inst Own-
SI1.5%
Earnings
Dilution
Financials Summary
Revenue$1.9M
Net Income-$37.89M
Total Assets$42.24M
Free Cash Flow$0
Debt & Equity
Equity 100%
Total Debt$0
Total Equity$17.34M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in RADX's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$42.24M
Liabilities$26.56M
Accounts Receivable$12.26M
Accounts Payable$3.84M
Inventory$0
PP&E (Net)$32K
Goodwill$0
Intangible Assets$26.81M
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD |
| Period Ending | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Revenue | $1.9M | $2.55M | $210K | $205K | $6K |
| YoY Growth | -25.5% | 1114.3% | 2.3% | 3210.6% | - |
| Cost of Revenue | $3.38M | $2.52M | $0 | $0 | $0 |
| Gross Profit | -$1.48M | $28K | $210K | $205K | $6K |
| Gross Margin | -77.7% | 1.1% | 100.0% | 100.0% | 100.0% |
| Research and Development | $0 | $19.33M | $12.33M | $9.69M | $2.9M |
| Selling, General, and Administrative | $11.14M | $11.61M | $10.69M | $9.15M | $7.62M |
| Other | $34.33M | -$4.09M | $2.91M | $5.6M | $3.48M |
| Total Operating Expenses | $45.47M | $26.84M | $25.94M | $24.45M | $14M |
| Operating Income (EBIT) | -$46.95M | -$26.82M | -$25.72M | -$24.24M | -$13.99M |
| Operating Margin | -2468.6% | -1050.6% | -12238.4% | -11803.3% | -225527.7% |
| Interest Expense | $77K | $46K | $452K | $60K | $6.57M |
| Interest Income | $0 | $624K | $35K | $102K | $0 |
| Other Income (Expense) | $7.86M | -$46K | -$7.89M | -$46K | -$7.29M |
| Income Before Tax (EBT) | -$39.09M | -$26.86M | -$33.61M | -$24.29M | -$21.28M |
| Income Tax Expense | -$37K | $73K | $68K | $27K | $31K |
| Net Income | -$37.89M | -$26.93M | -$33.68M | -$24.31M | -$21.31M |
| Net Income Margin | -1992.5% | -1055.3% | -16024.3% | -11838.6% | -343550.9% |
| Supplementary Data | |||||
| EPS | -4.56 | -5.28 | -36.00 | -33.00 | -29.76 |
| Diluted EPS | -4.56 | -5.28 | -36.00 | -33.00 | -29.76 |
| Weighted Average OS | 11.81M | 6.94M | 1.29M | 1.02M | 1.02M |
| EBITDA | -$45.02M | -$24.92M | -$31.05M | -$21.95M | -$12.62M |
| EBITDA Margin | -2367.2% | -976.3% | -14773.8% | -10685.9% | -203396.2% |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD |
| Period Ending | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Assets | |||||
| Current Assets | |||||
| Cash and Cash Equivalents | $2.91M | $20.45M | $13.05M | $8.22M | $18.95M |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $2.91M | $20.45M | $13.05M | $8.22M | $18.95M |
| Accounts Receivable | $12.26M | $7.31M | $694K | $3.14M | $40K |
| Inventory | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $239K | $237K | $2.31M | $94K | $161K |
| Total Current Assets | $15.4M | $28M | $16.05M | $11.45M | $19.15M |
| Long-Term Assets | |||||
| Property, Plant & Equipment Net | $32K | $38K | $43K | $48K | $1K |
| Goodwill | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $26.81M | $32.72M | $34.48M | $41.12M | $39.39M |
| Long-Term Investments | $0 | $0 | $28K | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $0 | $0 | $0 | $28K | $28K |
| Total Long-Term Assets | $26.84M | $32.75M | $34.55M | $41.2M | $39.42M |
| Other Assets | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $42.24M | $60.75M | $50.6M | $52.65M | $58.57M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | $3.84M | $4.46M | $4.52M | $2.08M | $836K |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $1.21M | $0 | $0 | $0 |
| Other Current Liabilities | $9.43M | $2.72M | $4.72M | $5.7M | $4.02M |
| Total Current Liabilities | $13.28M | $10.49M | $12.35M | $9.29M | $5.53M |
| Long-Term Liabilities | |||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $13.29M | $20.14M | $19.04M | $11.34M | $8.81M |
| Total Long-Term Liabilities | $13.29M | $20.14M | $19.04M | $11.34M | $8.81M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $26.56M | $30.63M | $31.39M | $20.63M | $14.34M |
| Stockholders' Equity | |||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $147.48M | $124.03M | $70.73M | $68.3M | $60.94M |
| Retained Earnings | -$140.26M | -$102.37M | -$78.21M | -$45.91M | -$21.65M |
| Comprehensive Income & Other | $10.13M | $9.21M | $26.64M | $7.28M | $4.94M |
| Other Stockholders' Equity | $10.13M | $9.81M | $27.24M | $8.79M | $4.94M |
| Total Equity | $17.34M | $31.46M | $19.76M | $31.18M | $44.23M |
| Minority Interest | -$1.66M | -$1.35M | -$540K | $839K | $0 |
| Total Liabilities and Equity | $43.9M | $62.1M | $51.14M | $51.81M | $58.57M |
| Supplementary Data | |||||
| Total Debt | $0 | $0 | $0 | $0 | $0 |
| Net Debt | -$2.91M | -$20.45M | -$13.05M | -$8.22M | -$18.95M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD |
| Period Ending | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Operating Activities | |||||
| Net Income | -$37.89M | $0 | -$33.68M | -$24.31M | -$21.31M |
| Depreciation & Amortization | $1.93M | $1.9M | $2.11M | $2.28M | $2.1M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $0 | $0 | $0 | $0 | $0 |
| Changes in Working Capital: | |||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $0 | $0 | $0 | $0 | $0 |
| Other Working Capital | $0 | $0 | $0 | $0 | $0 |
| Total Working Capital Change | $0 | $0 | $0 | $0 | $0 |
| Other Non-Cash Items | -$304K | -$27.64M | $15.43M | $5.73M | $12.25M |
| Net Cash from Operating | -$36.27M | -$25.74M | -$16.14M | -$16.3M | -$6.97M |
| Investing Activities | |||||
| Capital Expenditures | -$3.72M | $0 | $0 | -$32K | -$2K |
| Acquisitions | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | $1.24M | -$225K | -$1.04M | -$19.93M |
| Net Cash from Investing | -$3.72M | $1.24M | -$225K | -$1.08M | -$19.93M |
| Financing Activities | |||||
| Debt Repaid | - | $1.33M | -$1.55M | - | $41K |
| Common Stock Issuance | $22.93M | $37.92M | $20.82M | $7.08M | $49.17M |
| Common Stock Repurchases | $0 | $0 | -$1.08M | -$600K | -$3.39M |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | -$4.67M | -$82K | $0 | $0 |
| Net Cash from Financing | $22.93M | $31.91M | $21.21M | $6.48M | $45.74M |
| Forex Effect | $618K | -$10K | -$18K | $165K | $89K |
| Net Change in Cash | -$16.44M | $7.41M | $4.83M | -$10.73M | $18.93M |
| Supplementary Data | |||||
| Operating Cash Flow | -$36.27M | -$25.74M | -$16.14M | -$16.3M | -$6.97M |
| Capital Expenditure | $36.27M | $0 | $0 | -$1.08M | -$19.91M |
| Free Cash Flow | $0 | -$25.74M | -$16.14M | -$17.37M | -$26.87M |
| Cash at Beginning | $19.35M | $13.05M | $8.22M | $18.95M | $19K |
| Cash at End | $2.91M | $20.45M | $13.05M | $8.22M | $18.95M |